# Intravitreal Transplantation of Retinal Progenitor Cells Improves Outcome Measures in a Rat Model of Diabetic Retinopathy

**Authors:** Jing Yang, Geoffrey P. Lewis, Chin-Hui Hsiang, William Cho, Steven Menges, Kaili Ding, Gabriel Luna, Steven K. Fisher, Henry Klassen

PMC · DOI: 10.3390/ijms26199450 · 2025-09-27

## TL;DR

Injecting retinal progenitor cells into the eyes of diabetic rats improved both vision and retinal health, suggesting a potential new treatment for diabetic retinopathy.

## Contribution

This study demonstrates that intravitreal transplantation of retinal progenitor cells can provide both anatomical and functional benefits in a rat model of diabetic retinopathy.

## Key findings

- RPC treatment improved electroretinogram responses, optomotor response, and contrast sensitivity in diabetic rats.
- IHC analysis revealed reduced albumin extravasation, decreased VEGF expression, and better retinal morphology in treated eyes.
- Human RPCs also showed some positive effects, suggesting potential translational relevance.

## Abstract

Diabetic retinopathy (DR) is a major source of retinal disease and vision loss worldwide. Current treatments fail to address the loss of neurons and are associated with significant side effects. Here, we investigated whether retinal progenitor cells (RPCs) could improve anatomic and functional outcomes in a rat model of DR. Male Long Evans (LE) rats were given streptozotocin (STZ), and the induction of diabetes was confirmed prior to the intravitreal injection of RPCs, either allogeneic (no immunosuppression) or human (with cyclosporin A), at 1 week post-induction. Animals were tested at 6 weeks post-induction via electroretinogram (ERG), optomotor response (OR), and contrast sensitivity (CS). Retinas were harvested post-mortem, 8 weeks post-STZ induction, and analyzed using immunohistochemistry (IHC). In rat RPC-treated eyes, ERG (b-wave, oscillatory potentials), OR, and CS all showed a positive effect for cell treatment versus controls. IHC showed a markedly diminished extravasation of albumin, a decreased VEGF expression, and an improved morphology in cellular and synaptic layers. Human RPC-treated eyes replicated a subset of these results. Together, this provides evidence of both anatomic and functional treatment effects in a rat model of DR, encompassing retinal neuroprotection as well as improved vascular integrity, thereby supporting the further investigation of intravitreal RPCs for the treatment of this condition.

## Linked entities

- **Proteins:** VEGFA (vascular endothelial growth factor A)
- **Chemicals:** streptozotocin (PubChem CID 29327), cyclosporin A (PubChem CID 5284373)
- **Diseases:** diabetic retinopathy (MONDO:0005266)
- **Species:** Rattus norvegicus (taxon 10116), Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** Vegfa (vascular endothelial growth factor A) [NCBI Gene 83785] {aka VEGF-A, VEGF111, VEGF164, VPF, Vegf}, Alb (albumin) [NCBI Gene 24186] {aka Alb1, Albza}
- **Diseases:** diabetes (MESH:D003920), vision loss (MESH:D014786), retinal disease (MESH:D012164), DR (MESH:D003930)
- **Chemicals:** RPC (-), cyclosporin A (MESH:D016572), STZ (MESH:D013311)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12525025/full.md

---
Source: https://tomesphere.com/paper/PMC12525025